Clearmind Medicine Announces 1-for-30 Reverse Share Split
21 nov. 2023 08h15 HE
|
Clearmind Medicine Inc.
Following the reverse share split, the Company will have 607,381 Ordinary Shares issued and outstanding Tel Aviv, Israel / Vancouver, Canada, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Clearmind...
Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance
17 nov. 2023 16h15 HE
|
Clearmind Medicine Inc.
As part of the Company’s plan for recompliance, the Company’s shareholders approved a reverse stock split on November 14, 2023. Tel Aviv, Israel / Vancouver, Canada, Nov. 17, 2023 (GLOBE...
Clearmind Medicine Announces Shareholders Meeting Results
15 nov. 2023 07h37 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on...
Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities
09 nov. 2023 09h20 HE
|
Clearmind Medicine Inc.
Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial Tel Aviv, Israel / Vancouver, Canada,...
Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th
05 oct. 2023 09h00 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery...
Clearmind Medicine Closes US$2.25 Million Public Offering
18 sept. 2023 12h16 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and...
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering
14 sept. 2023 09h23 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and...
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
06 sept. 2023 09h20 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
14 août 2023 08h25 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery...
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
01 août 2023 09h00 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...